Combined Antiplatelet And Novel Oral Anticoagulant Therapy Is Increasingly Utilized But Associated With Worse Limb Outcomes And Equivalent Survival Compared To Antiplatelet And Warfarin And Antiplatelet Therapy Alone After Suprainguinal Bypass For Peripheral Artery Disease

Abstract

Recent trials have reported that combined antiplatelet and novel oral anticoagulant (NOAC) therapy reduces limb and cardiovascular events compared to antiplatelet therapy alone after infrainguinal surgical revascularization. The goal of this study is to compare long-term limb outcomes and survival in patients treated with antiplatelet + NOAC, antiplatelet + warfarin, and antiplatelet therapy alone after suprainguinal bypass.